The clinical potential of gene editing as a tool to engineer cell-based therapeutics
Abstract The clinical application of ex vivo gene edited cell therapies first began a decade ago with zinc finger nuclease editing of autologous CD4+ T-cells. Editing aimed to disrupt expression of the human immunodeficiency virus co-receptor gene CCR5, with the goal of yielding cells resistant to v...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-02-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40169-020-0268-z |